BLACK DIAMOND THERAPEUTICS, INC. Related Party Transaction, Expenses from Transactions with Related Party
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Related Party Transaction, Expenses from Transactions with Related Party of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty · last filed 2022-03-17
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for fiscal 2020 was $2.36M, a 77.29% decline from fiscal 2019.
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for fiscal 2019 was $10.41M, a 281.63% increase from fiscal 2018.
- BLACK DIAMOND THERAPEUTICS, INC. related party transaction, expenses from transactions with related party for fiscal 2018 was $2.73M.
| Period end | Related Party Transaction, Expenses from Transactions with Related Party 3 month | Related Party Transaction, Expenses from Transactions with Related Party 6 month | Related Party Transaction, Expenses from Transactions with Related Party 9 month | Related Party Transaction, Expenses from Transactions with Related Party 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | $71.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $71.00K derived: sum of 3 quarters · filed 2022-03-17 | $261.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $71.00K derived: sum of 2 quarters · filed 2022-03-17 | $261.00K derived: sum of 3 quarters · filed 2022-03-17 | $484.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $261.00K derived: sum of 2 quarters · filed 2022-03-17 | $484.00K derived: sum of 3 quarters · filed 2022-03-17 | $2.36M 10-K · filed 2022-03-17 |
| 2020-09-30 | $190.00K 10-Q · filed 2021-11-08 | $413.00K derived: sum of 2 quarters · filed 2021-11-08 | $2.29M 10-Q · filed 2021-11-08 | $3.85M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $223.00K 10-Q · filed 2021-08-12 | $2.10M 10-Q · filed 2021-08-12 | $3.66M derived: sum of 3 quarters · filed 2021-08-12 | $7.32M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.88M 10-Q · filed 2021-05-07 | $3.44M derived: sum of 2 quarters · filed 2021-05-07 | $7.09M derived: sum of 3 quarters · filed 2021-05-07 | $10.34M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $5.21M derived: sum of 2 quarters · filed 2021-03-25 | $8.46M derived: sum of 3 quarters · filed 2021-03-25 | $10.41M 10-K · filed 2021-03-25 |
| 2019-09-30 | $3.66M 10-Q · filed 2020-11-10 | $6.90M derived: sum of 2 quarters · filed 2020-11-10 | $8.85M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $3.25M 10-Q · filed 2020-08-11 | $5.20M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $1.95M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $2.73M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |